Vanguard Capital Management
DNTH icon

Vanguard Capital Management’s Dianthus Therapeutics DNTH Stock Holding History

Vanguard Capital Management’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$211M Buy
2,159,568
+128,319
+6% +$11.2M ﹤0.01% 1101
2026
Q1 		$170M Buy
+2,031,249
New +$118M ﹤0.01% 1154

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 247.39% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Vanguard Capital Management's DNTH Position: Q2 2026 in Review

Vanguard Capital Management increased its Dianthus Therapeutics (DNTH) stake by 6.3% in Q2 2026, buying an estimated $11.2M and bringing the position to 2,159,568 shares worth $211M. The position accounts for ﹤0.01% of the portfolio, ranked #1101.

Vanguard Capital Management first reported a position in DNTH in Q1 2026 and has held it in 2 quarters since. 244 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

  • Vanguard Capital Management held 2,159,568 shares of Dianthus Therapeutics worth $211M as of Q2 2026.
  • Vanguard Capital Management bought 128,319 Dianthus Therapeutics shares in Q2 2026, an estimated $11.2M.
  • Dianthus Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #1101 holding.
  • Vanguard Capital Management first reported a position in Dianthus Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 244 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.